About
Newsroom
Key facts for journalists and others writing about the programme, how we report progress, and how we correct mistakes.
Press kit
About us
NWPharmaTech Ltd is a UK company developing NWPT-SM32300, an investigational oral cannabidiol medicine, for people at clinical high risk of psychosis. A Phase 1 study in healthy volunteers (NCT07186283) was completed on 10 December 2025; a Phase 2B study is planned. NWPT-SM32300 is not approved for any use and its effectiveness is unproven.
| Company | NWPharmaTech Ltd, company number 13572461, England and Wales |
|---|---|
| Investigational medicine | NWPT-SM32300: 300 mg oral softgel capsule of highly purified cannabidiol |
| Regulatory status | investigational; not approved by any medicines regulator for any use |
| Completed study | Phase 1, 14 healthy adult volunteers aged 18 to 55; NCT07186283, ISRCTN25163383; completed 10 December 2025 |
| Planned study | Phase 2B in people at clinical high risk of psychosis: Planned. Not recruiting. |
| Media contact | +44 20 3693 3791 (head office) |
Progress
Dated events are listed on the updates page, and study milestones with their sources on the study page. No programme reports have been published.
Corrections log
No corrections have been made since publication.